Skye Bioscience Inc.(US:SKYE) Globenewswire·2025-11-29 13:28Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by January 16, 2026 [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Skye to discuss their legal options, particularly those who purchased securities between November 4, 2024, and October 3, 2025 [1][3]. - The firm has filed a federal securities class action against Skye, with a deadline for investors to seek lead plaintiff status by January 16, 2026 [3][7]. - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about the effectiveness of nimacimab and overstating its clinical and commercial prospects [5][6]. Group 2: Stock Performance and Impact - Following the announcement of disappointing clinical trial results for nimacimab on October 6, 2025, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 per share [6]. - The press release indicated that the primary endpoint of weight loss was not achieved in the clinical trial, and drug exposure was lower than expected, suggesting a need for higher dosing [6]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm encourages anyone with information regarding Skye's conduct, including whistleblowers and former employees, to contact them for further investigation [8].